Papulopustular Rosacea: Response to Treatment with Oral Azithromycin

Area of Science:

• Dermatology
• Pharmacology

Background:

• Papulopustular rosacea (PPR) often requires alternative treatments when standard therapies like oral tetracyclines and topical antibiotics fail.
• Refractory PPR cases present a clinical challenge, necessitating exploration of other therapeutic options.

Purpose of the Study:

• To evaluate the efficacy of oral azithromycin in patients with papulopustular rosacea (PPR) who were unresponsive to conventional treatments.
• To assess both short-term and long-term effectiveness of oral azithromycin for refractory PPR.

Main Methods:

• A prospective pilot study involved 16 patients diagnosed with PPR.
• Patients received oral azithromycin after failing to respond to oral doxycycline and metronidazole gel.
• Treatment response was assessed using clinical severity scales at baseline, post-treatment, and during 12-week follow-up intervals.

Main Results:

• All 16 participants showed improvement in their PPR symptoms after oral azithromycin treatment.
• Complete or near-complete recovery was observed in 87.5% (14 out of 16) of patients eight weeks post-treatment.
• Only two patients experienced recurrent inflammatory lesions during the follow-up period.

Conclusions:

• Oral azithromycin demonstrates significant potential as a highly effective treatment for papulopustular rosacea (PPR) resistant to standard therapies.
• The study suggests that oral azithromycin offers both short-term and sustained long-term benefits for refractory PPR.
• Further research into azithromycin for resistant rosacea is warranted based on these promising pilot findings.